When tyrosine kinase inhibitor sunitinib can be discontinued in metastatic renal cell carcinoma to pancreas: a case report

Table 1 Major laboratory results according to 03 cycles since sunitinib administration for 28 months

Parameter	May 2014	August 2014	November 2014	February 2015	May 2015	August 2015	November 2015	February 2016	May 2016	September 2016
Hb (g/dL)	14.2	13.3	13.5	13.7	13.2	13.6	13.9	14.1	13.8	13.9
WBC (× 10⁹/L)	4.89	4.10	5.02	4.67	4.90	5.15	4.77	4.07	5.08	4.78
PLT (× 10⁹/L)	205	198	175	189	176	154	132	120	115	120
TB (umol/L)	3	2	3	3
ALT (U/L)	16	19	20	14	19	21	22	16	15	14
AST (U/L)	12	11	13	13	14	13	15	17	13	11
BUN (g/L	0.25	0.25	0.32	0.40	0.4	0.42	0.42	0.39	0.31	0.43
BCr (mg/L)	11	11	12	11	9	10	11	11	10	11
Proteinuria	0	0	0	0	0	0	0	0	0	0
TSH (microUI/mL)	1.34	2.09	2.98	3.34	6.02	19.16	15.68	9.45	7.45	5.69

Normal ranges are given in parentheses as follows: Hb hemoglobin, WBC white blood cell (4.0–10.0 × 10⁹/L), PLT platelet (100–300 × 10⁹/L), TB total bilirubin (1.7–22.5 μmol/L), ALT alanine aminotransferase (5–45 U/L), AST aspartate aminotransferase (5–45 U/L), BUN blood urea nitrogen (0.17–0.49 g /L), BCr Blood creatinine (7–12 mg/L), TSH thyroid-stimulating hormone (0.27–4.20 microUI/mL)

ISSN: 1752-1947